TMCnet News
Research and Markets: Innovative Drug R&D in China 2014 - New Developments and Future ProspectsDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/4d9kcf/innovative_drug) has announced the addition of the "Innovative Drug R&D in China 2014 - New Developments and Future Prospect, 2nd Edition" report to their offering. The report is a must-read book to global pharmaceutical and biotechnology companies that are seeking research collaboration with Chinese organizations, venture capital investors interested in investment opportunities in the Chinese pharmaceutical and biotechnology industries, market research/consultancy firms seeking the information of the development situation of China's drug R&D industry, and even the government agencies of those countries that are interested in learning the current and future development of China's biotechnology industry. Key Topics Covered: Executive Summary
Chapter One - Current State of Innovative Drug R&D in China 1.1 Introduction 1.2 Current basic &D infrastructure in China 1.3 Current state of Chinese biotechnology industry 1.4 Current key forces in China's innovative drug R&D industry 1.5 Current R&D funding situations in China 1.6 Current R&D spending levels of Chinese drug companies 1.7 China's current overall capability in innovative drug R&D 1.8 Current pipelines of China's innovative drug R&D Chapter Two - Current Key Players and Their Pipelines of China's Innovative Drug R&D Industry 2.1 Introduction 2.2 Latest developments of small molecule drug R&D in China - Major players, their capabilities and pipelines 2.3 Latest developments of antibody drug R&D in China - Major players, their capabilities and pipelines 2.4 Latest developments of protein drug R&D in China - Major players, their capabilities and pipelines 2.5 Latest developments of vaccine R&D in China - Major players, their capabilities and pipelines 2.6 Latest developments of biosimilar R&D in China - Major players, their capabilities and pipelines 2.7 Latest developments of traditional Chinese medicine R&D in China - Major players, their capabilities and pipelines Chapter Three - Multinational Drug Companies' Current China R&D Strategies and Activities 3.1 Introduction 3.2 China's attractions to global drug companies 3.3 Current R&D strategies of global major pharma and biopharma companies in China 3.4 Global major pharma/biopharma companies conducting R&D in China 3.5 Multinational biotech companies conducting drug R&D in China Chapter Four - Analysis of Future Development Potentials of Innovative Drug R&D in China 4.1 Introduction 4.2 Analysis of China's current strengths and weaknesses in innovative drug R&D 4.3 Innovative drug R&D supported by Chinese government 4.4 Increasing funding opportunities to drug R&D-focused Chinese companies 4.5 Analysis of future possible R&D strategies of global major pharma/biopharma companies in China 4.6 Analysis of global drug R&D competitive landscape Chinese companies going to face 4.7 Future development potentials of innovative drug R&D in China Companies Mentioned - Amgen - AstraZeneca - BMS' China R&D activities - Bayer Healthcare - Eli Lilly - GSK - Johnson & Johnson - Merck - Merck Serono - Novartis - Novo Nordisk - Pfizer - Roche - Sanofi - Takeda For more information visit http://www.researchandmarkets.com/research/4d9kcf/innovative_drug
|